Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

Stock Information for Aptevo Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aptevo Therapeutics Inc.

Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.